HemoBioTech receives patent for HemoTech treatment of acute blood loss

HemoBioTech (Pink Sheets:HMBT) announced today the issuance of a new patent US 7,759,306 B2, "Methods of Treating Acute Blood Loss." HemoBioTech has an exclusive worldwide license from Texas Tech University to commercialize the technology. The new patent continues to May 16, 2026.

“The major advance in HemoTech is the presence of Adenosine which has anti-inflammatory activity.”

The new patent involves HemoTech which induces the production of new red blood cells in the body. Uses for HemoTech could involve the treatment of acute blood loss and anemia in trauma, surgery, cancer, kidney disease and heart disease. The market for treatment of acute anemia is over $2 billion.

HemoTech also has the advantage of delivering oxygen to tissue in the body since it is composed of modified hemoglobin. The combination of delivering oxygen and inducing new red blood cells could be an advantage for treating trauma, elective surgery in third world countries plagued with a high incidence of HIV or Hepatitis contaminated blood and for use by the military and homeland security.

HemoTech is composed of bovine hemoglobin, which is chemically modified with ATP, Adenosine and GSH, to overcome toxicity. HemoTech has been used successfully in an initial clinical study to treat children afflicted with sickle cell anemia, with no apparent side affects. HemoTech stabilizes a cell factor called Hif-1 alpha, which results in induction of erythropoietin, which stimulates an increase in production of new red blood cells.

"HemoTech addresses a multi-billion dollar market for treatment of acute blood loss and anemia with the potential advantage of fewer side affects and the ability to deliver oxygen in acute situations," said Dr. Arthur P. Bollon, Chief Executive Officer of HemoBioTech. "The major advance in HemoTech is the presence of Adenosine which has anti-inflammatory activity."